Eli Lilly EMC2
Development and Evaluation of an Electronic health Record-based Medication Complete Communication (EMC2) Strategy
December 2015 - March 2020
Eli Lilly and Company
Nearly 10 million outpatient physician visits and 4 million emergency department admissions occur each year because of adverse drug events or serious drug side effects. A risk communication and surveillance strategy is needed in primary care to ensure that patients are adequately informed about medication risks and are taking high-risk drugs safely. This trial evaluates the impact and scalability of a primary care based 'EMC2' strategy designed by our team to promote safe medication use and adherence.
The EHR-based Medication Complete Communication (EMC2) Strategy, which we are testing via a 2-arm, multi-site, physician-randomized pragmatic trial, is designed to: 1) inform patients about medication risks and safe use, 2) promote provider education and counseling about prescribed drugs and 3) monitor patient adherence outside of visits. It includes the following elements:
1) Prescribers will receive a ‘Best Practices Alert’ which recommends patient counseling on medication use and provides an overview of key medication risks
2) Patients will receive a Medication Guide + Summary with their After Visit Summary
3) Patients will be asked to complete a brief questionnaire on medication use via the patient portal post visit (at both 1 week and 1 month post visit for this phase of the study)
4) Portal assessment results and feedback will be provided to the clinic via an inbox message. Clinic staff will respond to any identified problems according to their own clinical care protocols.
• Principal Investigators: Michael S. Wolf, PhD MPH; Stacy Cooper Bailey, PhD MPH
• Project Lead: Pauline Zheng